PolPharma

Trelleborg A.B. plans to strengthen its position in the life sciences market and develop a strong platform in the sector by acquiring Speciality Silicone Fabricators, a manufacturer of high-precision medical silicone products.

"The acquisition is expected to be completed by the second quarter of 2016."

The acquisition is expected to be completed by the second quarter of 2016.

Polpharma S.A., a manufacturer of drug products and active pharmaceutical ingredients (API), has announced its acquirement of biopharmaceutical company EPIRUS Biopharmaceuticals.

Pursuant to the agreement, Polpharma will acquire EPIRUS Netherlands’ proprietary CHOBC cell line platform, a fully-equipped laboratory and bioreactor capabilities for the development of monoclonal antibodies and protein therapeutics, while EPIRUS Biopharma will retain exclusive rights to develop BOW080 and BOW070 for the treatment of ultra-rare blood disorder and uncommon lymphoproliferative disorder respectively.

The acquisition will enable Polpharma to expand its portfolio and EPIRUS Biopharma to pursue its reconstructing efforts of creating a separate company focused on rare disease biological products.


Image: Polpharma S.A.has announced its acquirement of EPIRUS Biopharmaceuticals. Photo: Courtesy of polpharmacommons.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now